Clinical value of carcinoembryonic antigen in mammary neoplasms of bitches.
CEA
biomarkers
canine mammary tumour
metastasis
prognosis
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
28
08
2019
revised:
17
10
2019
accepted:
22
10
2019
pubmed:
31
10
2019
medline:
14
7
2021
entrez:
31
10
2019
Statut:
ppublish
Résumé
This study aimed at evaluating the behaviour and understanding the diagnostic value of the carcinoembryonic antigen (CEA) in bitches with mammary carcinoma as a tool for monitoring and prognosis of canine cancer patients. Serum samples from 77 bitches were divided into four groups, G1 (n = 21), control group (healthy/neoplasia free bitches); G2 (n = 31), bitches with non-metastatic mammary carcinoma less than 3 cm; G3 (n = 12), bitches with non-metastatic mammary carcinoma greater than 3 cm; and, G4 (n = 13) bitches with mammary carcinoma and lymph node metastasis. The marker was dosed once in G1, whereas in G2, G3 and G4, CEA levels were determined before (M0) and 15 days after (M1) mastectomy, using the ELISA kit for humans while reading used ELISYS ONE human. A group of 11 bitches was followed up 45 days after mastectomy (M2). The results for the concentration of markers in blood serum samples at the evaluated times and their relationship with neoplasia biological behaviour and observed clinicopathological changes were evaluated by the Tukey test at 5% significance. The ROC curve was established to find the cut-off value and calculate the test sensitivity and specificity, the multivariate matching analysis was performed to confirm the association between CEA values and clinicopathological variables. CEA values increased significantly in bitches with mammary carcinoma, metastatic tumours with a diameter larger than 3.0 cm and high grade, compared with healthy ones. In addition, mastectomy reduced the CEA concentration in the blood (P < .05) whereas high CEA levels were associated with unfavourable prognostic factors (P < .05). The biomarker presented good diagnostic value, especially for more aggressive tumours. In conclusion, CEA serum concentrations allowed to follow efficiently the evolution of mammary tumours in bitches, since CEA values increased in bitches with mammary gland tumour and decreased after mastectomy while correlating with prognostic factors such as tumour size, nodal metastasis and histological grade. Further studies are still needed to confirm its diagnostic value for follow-up of relapse and early metastasis.
Substances chimiques
Biomarkers, Tumor
0
Carcinoembryonic Antigen
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
315-323Subventions
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2015/15015-9
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2016/00128-5
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 2005;438(7069):803.
Uva P, Aurisicchio L, Watters J, et al. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics. 2009;10(1):135.
Shafiee R, Javanbakht J, Atyabi N, et al. Diagnosis, classification, and grading of canine mammary tumours as a model to study human breast cancer: a clinico-cytohistopathological study with environmental factors influencing public health and medicine. Cancer Cell Int. 2013;13:79.
De Nardi AB, Rodaski S, Rocha NS, Fernandes SC. Breast neoplasms. In: Daleck CR, de Nardi AB, eds. Oncology in Dogs and Cats. 2nd ed. São Paulo, Brazil: Roca, Inc; 2016:372-383.
Klopfleisch R, Gruber AD. Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Res Vet Sci. 2009;87:91-96.
Sorenmo K. Canine mammary gland tumours. Vet Clin Small Anim Pract. 2003;33(3):573-596.
Cavalcanti MF, Cassali GD. Prognostic factors in clinical and histopathological diagnosis of breast tumors in bitches-review. Rev Clin Vet. 2006;11:56-64.
Pitteri SJ, Amon LM, Buson TB, et al. Detection of elevated plasma levels of EGF receptor prior to breast cancer diagnosis among hormone therapy users. Cancer Res. 2010;70:8598-8606.
Zhang SJ, Hu Y, Qian HL, et al. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev. 2013;14:3937-3940.
De Nardi AB, Daleck CR, Laufer-Amorim R, et al. Correlation of cyclooxygenase-2 with the prognosis of mammary carcinomas of bitches. Acta Sci Vet. 2007;35(27):619.
Gama A, Paredes J, Gärtner F, et al. Expression of E-cadherin, P-cadherin and β-catenin in canine malignant mammary tumors in relation to clinicopathological parameters, proliferation and survival. Vet J. 2008;177(45):53.
Cassali GD, Lavalle GE, Ferreira E, et al. Consensus for the diagnosis, prognosis and treatment of canine mammary tumors-2013. BJVP. 2014;7(2):38-69.
Harris L, Fritsche H, Mennel R. American Society of Clinical Oncology 2007: update of recommendations for the use tumor markers in breast cancer. JCO. 2007;25:5287-5312.
Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. IJCO. 2008;13(5):447-451.
Capelozzi VL. Understanding the role of biological markers in lung cancer. J Pneumol. 2001;27(6):321-328.
Souza JV. Mucinous markers associated with cancer. J AMRIGS. 2002;46:70-83.
Kasper DL, Braunwald E, Fauci AS, et al. Harrisons Principles of Internal Medicine. Part Five: Oncology and Hematology. Section 1: Neoplastic Disorders. 16th ed. New York: McGraw-Hill Education, Inc; 2004:240-250.
Wang G, Qin Y, Zhang J, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci. 2014;15(6):9546-9565.
Wu SG, He ZY, Zhou J, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014;23:88-93.
Manuali E, De Giuseppe A, Feliziani F, et al. CA 15-3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade. BMC Vet Res. 2012;8(1):86.
Campos LC, Lavalle GE, Estrela-Lima A, et al. CA15.3, CEA, and LDH in dogs with malignant mammary tumors. J Vet Intern Med. 2012;26(1383):88.
Marchesi MC, Manuali E, Pacifico E, et al. Cancer antigen 15/3: possible diagnostic use in veterinary clinical oncology. Preliminary study. Vet Res Commun. 2010;34(1):103-106.
Roberto GB, Ziliotto L, Seki MC. Comparative evaluation of CA 15-3 tumor marker dosage in healthy bitches or with mammary neoplasia. Pesqui Vet Bras. 2018;38(9):1800-1807.
Ledecky V, Valencakova-Agyagosova A, Lepej J, et al. Determination of carcinoembryonic antigen and cancer antigen values with the radioimmunoassay method in healthy females dogs. Vet Med. 2013;58(5):277-283.
Goldshmidt M, Pena L, Rasotto R, et al. Classification and grading of canine mammary tumors. Vet Pathol. 2011;48:117-131.
Owen LN. TNM Classification of Tumors in Domestic Animals. Geneva: World Health Organization; 1980.
Yamagami T, Kobayashi T, Takahashi K, et al. Prognosis for canine malignant mammary tumors based on TNM and histologic classification. J Vet Med Sci. 1996;589(11):1079-1083.
Elston CW, Ellis IO. Assessment of histological grade. In: Elston CW, Ellis IO, eds. Systemic Pathology. The Breast. London: Churchill Livingstone, Inc; 1998:365-384.
Valencakova-Agyagosova A, Frischova Z, Sevcikova Z, et al. Determination of carcinoembryonic antigen and cancer antigen (CA 15-3) in bitches with tumours on mammary gland: preliminary report. Vet Comp Oncol. 2012;12(3):205-214.
Al-Jarallah MA, Behbehani AE, El-Nass SA, et al. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol. 1993;19(1):74-79.
Samy N, Ragab HM, Maksoud E, Abd N, Shaalan M, et al. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomarkers. 2010;6(2):63-72.
Tahari Z, Medjdoub A, Sahraoui T, Belhabri L, El Kebir FZ, et al. Study of serum carcinoembryonic antigen's profile for breast cancer in Western Algeria: 100 cases. Gulf J Oncol. 2017;1(23):33.
Sorenmo K. Canine mammary gland tumors. Vet Clin Small Anim Pract. 2003;33(3):573-596.
Tang S, Zhou F, Sun Y, Wei L, Zhu S, et al. CEA in breast ductal secretions as a promising biomarker for the diagnosis of breast cancer: a systematic review and meta-analysis. Breast câncer. 2016;23(6):813-819.
Wang W, Xu X, Tian B, Wang Y, Du L, et al. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta. 2017;470:51-55.
Senhorello ILS, Terra EM, Sueiro FAR, et al. Clinical value of carcinoembryonic antigen in breast neoplasms of female dogs. Figshare; Paper. 2019. https://doi.org/10.6084/m9.figshare.8020985.v1.